Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
Joining the Big Pharma rush to pick up potentially valuable gene therapy tech, Roche has expanded its partnership with 4D Molecular Therapeutics to work on a drug for night blindness, among other ophthalmology programs.
Roche had first partnered with the Emeryville, California-based biotech back in 2016, when the duo was researching a small handful of rare retinal disease indications. Now, it’s expanded that commitment to take in ophthalmology programs that include prospects for much larger markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
